Evidence map›Paper›PMID 34356658›Full record

ArticleBiomolecules2021

Loss of the MAF Transcription Factor in Laryngeal Squamous Cell Carcinoma.

Joanna Janiszewska, Magdalena Bodnar, Julia Paczkowska, Adam Ustaszewski, Maciej J Smialek, Lukasz Szylberg, Andrzej Marszalek, Katarzyna Kiwerska, Reidar Grenman, Krzysztof Szyfter and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.International journal of molecular sciences · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Joanna JaniszewskaInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.ORCID 0000-0002-1765-0152
Magdalena BodnarDepartment of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.
Julia PaczkowskaInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Adam UstaszewskiInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.ORCID 0000-0002-9542-0029
Maciej J SmialekInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.ORCID 0000-0002-8042-7965
Lukasz SzylbergDepartment of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.
Andrzej MarszalekDepartment of Oncologic Pathology and Prophylactics, Poznan University of Medical Sciences and Greater Poland Cancer Center, 61-866 Poznan, Poland.ORCID 0000-0002-6055-9151
Katarzyna KiwerskaInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Reidar GrenmanDepartment of Otorhinolaryngology-Head and Neck Surgery, Turku University and Turku University Hospital, 20-500 Turku, Finland.
Krzysztof SzyfterInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Malgorzata WierzbickaInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.ORCID 0000-0003-0006-6352
Maciej GiefingInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.ORCID 0000-0002-4760-8246
Malgorzata Jarmuz-SzymczakInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Institute of Human Genetics · PLPoznan University of Medical Sciences · PLNicolaus Copernicus University · PLGreater Poland Cancer Center · PLTurku University Hospital · FI

Funding

European Union under the European Social Fund Scholarship support for Ph.D. students specializing in majors strategic for Greater Poland's de-velopment for year 2013/2014, Sub-measure 8.2.2 Human Capital Operational Program.
6 · The paper itself

Abstract

MAF is a transcription factor that may act either as a tumor suppressor or as an oncogene, depending on cell type. We have shown previously that the overexpressed miR-1290 influences MAF protein levels in LSCC (laryngeal squamous cell carcinoma) cell lines. In this study, we shed further light on the interaction between miR-1290 and

Indexed as

3' Untranslated RegionsAgedCell Line, TumorCell NucleusDNA MethylationFemaleGene DosageGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansMaleMicroRNAsMiddle AgedMutationPromoter Regions, GeneticProto-Oncogene Proteins c-maf3' Untranslated RegionsMAF protein, humanMicroRNAsMIRN1290 microRNA, humanProto-Oncogene Proteins c-mafapoptosislaryngeal squamous cell carcinomaMAFmicroRNAsmiR-1290transcription factor

Identifiers

PMID34356658
PMCPMC8301809
OpenAlexW3181606325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.